Analysis of Antibody Responses to Mycobacterium leprae Phenolic Glycolipid I, Lipoarabinomannan, and Recombinant Proteins To Define Disease Subtype-Specific Antigenic Profiles in Leprosy
- 1 February 2011
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 18 (2), 260-267
- https://doi.org/10.1128/cvi.00472-10
Abstract
A simple serodiagnostic test based on the Mycobacterium leprae -specific phenolic glycolipid I(PGL-I), for individuals with leprosy is nearly universally positive in leprosy patients with high bacillary loads but cannot be used as a stand-alone diagnostic test for the entire spectrum of the disease process. For patients with early infection with no detectable acid-fast bacilli in lesions or with low or no antibody titer to PGL-I, as in those at the tuberculoid end of the disease spectrum, this diagnostic approach has limited usefulness. To identify additional M. leprae antigens that might enhance the serological detection of these individuals, we have examined the reactivity patterns of patient sera to PGL-I, lipoarabinomannan (LAM), and six recombinant M. leprae proteins (ML1877, ML0841, ML2028, ML2038, ML0380, and ML0050) by Western blot analysis and enzyme-linked immunosorbent assay (ELISA). Overall, the responses to ML2028 (Ag85B) and ML2038 (bacterioferritin) were consistently high in both multibacillary and paucibacillary groups and weak or absent in endemic controls, while responses to other antigens showed considerable variability, from strongly positive to completely negative. This analysis has given a clearer understanding of some of the differences in the antibody responses between individuals at opposite ends of the disease spectrum, as well as illustrating the heterogeneity of antibody responses toward protein, carbohydrate, and glycolipid antigens within a clinical group. Correlating these response patterns with a particular disease state could allow for a more critical assessment of the form of disease within the leprosy spectrum and could lead to better patient management.Keywords
This publication has 35 references indexed in Scilit:
- A modified synthesis and serological evaluation of neoglycoproteins containing the natural disaccharide of PGL-I from Mycobacterium lepraeBioorganic & Medicinal Chemistry Letters, 2010
- From Genome-Based In Silico Predictions to Ex Vivo Verification of Leprosy DiagnosisClinical and Vaccine Immunology, 2009
- Selection of Antigens and Development of Prototype Tests for Point-of-Care Leprosy DiagnosisClinical and Vaccine Immunology, 2008
- The Prevalence of Previously Undiagnosed Leprosy in the General Population of Northwest BangladeshPLoS Neglected Tropical Diseases, 2008
- Evaluation of major membrane protein-II as a tool for serodiagnosis of leprosyFEMS Microbiology Letters, 2007
- The Continuing Challenges of LeprosyClinical Microbiology Reviews, 2006
- ML0405 and ML2331 Are Antigens ofMycobacterium lepraewith Potential for Diagnosis of LeprosyClinical and Vaccine Immunology, 2006
- Massive gene decay in the leprosy bacillusNature, 2001
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- T‐Cell Stimulation with Purified Mycobacterial Antigens in Patients and Healthy Subjects infected with Mycobacterium leprae: Secreted Antigen 85 is Another Immunodominant AntigenScandinavian Journal of Immunology, 1993